Table 2.
Comparison of risk factors between infected and uninfected groups.
| Risk factors | Uninfected patients (n = 86) |
Infected patients (n = 86) |
p |
|---|---|---|---|
| Sex % | |||
| Female | 55.9 | 50.0 | 0.637 |
| Male | 44.1 | 50.0 | |
| Age (month)∗ | 32.0 (9.0–58.0) | 57.5 (33.5–91.0) | 0.286 |
| Intensive care stay % | 36.0 | 52.3 | 0.061 |
| Length of hospital stay (days)∗ | 30.0 (20.0–51.0) | 7.0 (3.0–12.0) | <0.001 |
| Unconsciousness % | 16.2 | 46.5 | <0.001 |
| Prolonged hospitalization % | 12.8 | 67.4 | <0.001 |
| Use of central venous catheter % | 2.3 | 24.4 | <0.001 |
| Enteral feeding via a nasogastric tube % | 23.2 | 54.6 | <0.001 |
| Transfusion % | 17.4 | 53.4 | <0.001 |
| Parenteral nutrition % | 6.9 | 17.4 | 0.036 |
| Use of H2 receptor blockers % | 25.5 | 43.0 | 0.016 |
| Mechanical ventilation % | 13.9 | 45.3 | <0.001 |
| Use of urinary catheter % | 4.6 | 43.0 | <0.001 |
| Neutropenia % | 6.9 | 23.2 | 0.003 |
| Use of port % | 4.6 | 13.9 | 0.036 |
| Use of third-generation cephalosporins % | 24.4 | 38.3 | 0.049 |
| Use of carbapenems % | 11.6 | 55.8 | <0.001 |
| Use of steroid % | 8.1 | 6.9 | 0.773 |
| Use of aminoglycosides % | 3.4 | 24.4 | 0.001 |
| Use of glycopeptides % | 4.6 | 38.3 | <0.001 |
∗Median and interquartile ranges (25th and 75th percentile).